Provided herein is a coated coronary stent, comprising: a. stent; b. a plurality of layers deposited on said stent to form said coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.
1. A coated stent comprising
a. a stent comprising a plurality of stent struts;
b. a coating comprising an active agent and a bioabsorbable polymer, wherein the active agent is a macrolide immunosuppressive drug in crystalline form, the coating formed under conditions that do not substantially modify the morphology of the drug, and wherein the active agent remains in crystalline form after being included in the coating;
wherein said coating is substantially conformal to abluminal, luminal, and sidewall surfaces of the struts of the stent to form a plurality of coated stent struts; wherein a ratio of an abluminal coating thickness to a luminal coating thickness is at most 90:10,
wherein a coated stent strut thickness measured from the abluminal surface of the coated stent strut to the luminal surface of the coated stent strut is at most 75 microns.
2. The coated stent of claim 1 , wherein the ratio of abluminal coating thickness to luminal coating thickness is at least one of: at most 50:50, at most 65:35, at most 70:30, and at most 80:20.
3. The coated stent of claim 1 , wherein the ratio of abluminal coating thickness to luminal coating thickness is achieved during coating of the stent with the coating without a masking element.
4. The coated stent of claim 1 , wherein the ratio of abluminal coating thickness to luminal coating thickness is achieved during coating of the stent with the coating without shielding the luminal surfaces.
5. The coated stent of claim 1 wherein the ratio of abluminal coating thickness to luminal coating thickness is achieved during coating of the stent with the coating wherein the stent is in at least one of: a collapsed condition, an expanded condition, and an intermediate condition.
6. The coated stent claim 1 , wherein an average coated stent strut thickness when measured from the abluminal surface of the coated stent strut to the luminal surface of the coated stent strut is at least one of: at most 65 microns, and at most 63 microns.
7. The coated stent of claim 1 , wherein the coating contacts at least one of: at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% of the abluminal, luminal, and sidewall surfaces of the struts of the stent.
8. The coated stent of claim 7 , wherein contact of the coating to the stent surfaces is measured by scanning electron microscopy of at least one cross section of a strut of the stent.
9. The coated stent of claim 7 , wherein contact of the coating is measured when the stent is at least one of: in a collapsed condition, and in an expanded condition.
10. The coated stent of claim 1 , wherein the macrolide immunosuppressive (limus) drug comprises rapamycin.
11. The coated stent of claim 1 , wherein at least 50%, 60%, 70%, 80%, 90%, or 100% of the macrolide immunosuppressive (limus) drug is in crystalline or semi-crystalline form.
12. The coated stent of claim 1 , wherein the coating adds at most 17 microns thickness to the coated stent.
13. The coated stent of claim 1 , wherein the abluminal coating thickness is an average of a plurality of measurements along the abluminal surface, and wherein the luminal coating thickness is an average of a plurality of measurements along the luminal surface.
14. The coated stent of claim 1 , wherein the abluminal coating thickness is a single measurement near the center of the abluminal surface, and wherein the luminal coating thickness is a single measurement near the center of the luminal surface.
15. The coated stent of claim 1 , wherein the bioabsorbable polymer comprises 50:50 poly(d,l-lactide-co-glycolide).